Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has...
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has...
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it...
Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA)...
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic...
The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement...
Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has...
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
Ultrasound Biotechnology, the Shanghai-based wholly owned subsidiary of US firm Ultrasound Wondering, Inc., has announced...
Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...
Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...
Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...